Patent application number | Description | Published |
20090017536 | MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera. | 01-15-2009 |
20100011451 | PHENOTYPIC AND GENOTYPIC DIFFERENCES OF MVA STRAINS - The present invention provides kits and methods to screen viral nucleic acids for a profile of genetic deletions and mutations, optionally in combination with one or more assays for viral replication and/or attenuation capacity. | 01-14-2010 |
20110052627 | RECOMBINANT MODIFIED VACCINIA VIRUS MEASLES VACCINE - The invention concerns methods, compositions and kits for use in preparing a medicament and vaccine for measles virus comprising an Attenuated Modified Vaccinia Virus Ankara (MVA) strain encoding hemagglutinin protein, fusion protein, and nucleoprotein of measles virus (MVA-Measles). The recombinant virus induced superior cellular and humoral responses to the measles virus when compared to Measles vaccine Rouvax®. Both T cell and B cell immune responses to the recombinant MVA were observed not only in adult animals, but also in newborn and juvenile animals. Results in adult humans showed that MVA-Measles induces a strong immune response, is safe and well tolerated. | 03-03-2011 |
20110135683 | MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCNATION OF NEONATES - The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. | 06-09-2011 |
20110159032 | MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES - The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3. | 06-30-2011 |
20110172407 | PHENOTYPIC AND GENOTYPIC DIFFERENCES OF MVA STRAINS - The present invention provides kits and methods to screen viral nucleic acids for a profile of genetic deletions and mutations, optionally in combination with one or more assays for viral replication and/or attenuation capacity. | 07-14-2011 |
20110217757 | MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera. | 09-08-2011 |
Patent application number | Description | Published |
20090104224 | MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES - The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. | 04-23-2009 |
20090169579 | Modified vaccinia Ankara virus avriant - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 07-02-2009 |
20100119545 | MODIFIED VACCINIA ANKARA VIRUS VARIANT - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 05-13-2010 |
20100183663 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 07-22-2010 |
20100196992 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 08-05-2010 |
20100279386 | MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera. | 11-04-2010 |
20110142877 | Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents - The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents. | 06-16-2011 |
20110182932 | MODIFIED VACCINIA ANKARA VIRUS VARIANT - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 07-28-2011 |
20110182933 | MODIFIED VACCINIA ANKARA VIRUS VARIANT - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 07-28-2011 |
20110306093 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 12-15-2011 |
20120009214 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 01-12-2012 |
20120014922 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 01-19-2012 |
20120015423 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 01-19-2012 |
20120107359 | USE OF A MODIFIED POXVIRUS FOR THE RAPID INDUCTION OF IMMUNITY AGAINST A POXVIRUS OR OTHER INFECTIOUS AGENTS - The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents. | 05-03-2012 |
Patent application number | Description | Published |
20120135032 | GENERATION OF A BROAD T-CELL RESPONSE IN HUMANS AGAINST HIV - The present invention relates to a recombinant Modified Vaccinia virus Ankara (MVA) comprising in the viral genome one or more expression cassettes for the expression of HIV proteins selected from Gag, Pol, Tat, Vif, Vpu, Vpr, Rev and Nef or a part or a derivative thereof or selected from Gag, Pol, Vpu, Vpr, Rev and Nef or a part or a derivative thereof for use as medicament or vaccine and its use for the treatment and/or prevention of HIV infections and AIDS. | 05-31-2012 |
20120183574 | MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCNATION OF NEONATES - The invention concerns the use of a virus for the preparation of a medicament for the vaccination or treatment of a human, wherein the virus is capable of infecting the cells of the human, but not capable of being replicated to infectious progeny virus in the human. The virus is preferably a Modified Vaccinia Virus Ankara. | 07-19-2012 |
20120276613 | MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera. | 11-01-2012 |
20120328650 | MODIFIED VACCINIA ANKARA VIRUS VARIANT - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 12-27-2012 |
20140322265 | RECOMBINANT POXVIRUS VECTOR COMPRISING TETANUS TOXIN FRAGMENT C - The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment C for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment C (TTC) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject. | 10-30-2014 |
20140341946 | USE OF A MODIFIED POXVIRUS FOR THE RAPID INDUCTION OF IMMUNITY AGAINST A POXVIRUS OR OTHER INFECTIOUS AGENTS - The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents. | 11-20-2014 |
20150174238 | POXVIRAL VECTORS FOR LOW ANTIBODY RESPONSE AFTER A FIRST PRIMING IMMUNIZATION - The invention is drawn to compositions and methods for the induction of an immune response, in particular a strong CD8 T cell response, to a specific antigenic determinant without raising a significant antibody response to the antigenic determinant after a first, priming immunization. The method comprises administering to the host a recombinant poxviral vector comprising a transcriptional control element comprising an early and/or late element linked to a nucleotide sequence encoding the antigenic determinant. The recombinant poxviral vector comprises a transcriptional control element comprising an early and/or late element linked to a nucleotide sequence encoding the antigenic determinant. The late element may be stronger than the cowpox ATI promoter in HeLa cells. | 06-25-2015 |
20150209421 | RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE - Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection. | 07-30-2015 |